1. Home
  2. Companies
  3. OIL
  4. Material Events

Optiscan Imaging (ASX:OIL) — Material Events

ASX:OIL · 13 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 12 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
Optiscan Launches InSpecta™ in US Veterinary Market After FDA ApprovalMedium
Optiscan launches InSpecta™ veterinary imaging device in U.S. after FDA approval
7 July 2026 ·Product Launch and Regulatory Update ·85
Optiscan Launches US Breast Cancer Imaging Study with Mayo Clinic to Support FDA FilingsMedium
Optiscan initiates US breast cancer imaging study with Mayo Clinic to support FDA submissions
22 July 2026 ·Research Agreement Announcement ·85
Optiscan Accelerates Clinical Trials and FDA Prep with Key PartnershipsMedium
Optiscan advances clinical studies and partnerships, boosts cash receipts, and prepares for 2026 FDA submissions
30 Jan 2026 ·Quarterly Activities & Cashflow Report ·85
Optiscan Raises $17.75m to Accelerate Clinical Trials and FDA Approval PathwayMedium
Optiscan raises $17.75m, advances clinical studies and FDA preparations with strong cash position
28 Oct 2025 ·Appendix 4C Quarterly Activities & Cashflow Report ·85
Optiscan Accelerates Head and Neck Cancer Imaging Trial at St John of GodMedium
Optiscan's Head and Neck Cancer Imaging Study Advances Ahead of Schedule
21 July 2026 ·Clinical Study Progress Update ·85
Optiscan lodges FDA dossier for InSpecta and advances clinical trials for US market pushHigh
Optiscan lodges FDA dossier for InSpecta®, advances clinical studies and prepares US veterinary market launch
30 Apr 2026 ·Quarterly Activities & Cashflow Report ·85
Optiscan Launches Pioneering Head and Neck Cancer Imaging Study in PerthMedium
Optiscan launches first-in-human head and neck cancer imaging study in Australia
3 Dec 2025 ·Clinical Study Initiation Announcement ·85
Optiscan Advances US Veterinary Market Entry with FDA Dossier SubmissionMedium
Optiscan submits FDA dossier for InSpecta®, advancing U.S. veterinary market entry
31 Mar 2026 ·Regulatory Submission Announcement ·85
Optiscan and ACL Join Forces to Revolutionize Real-Time Digital PathologyMedium
Optiscan and Australian Clinical Labs Partner to Advance Real-Time Digital Pathology
10 Nov 2025 ·Strategic Collaboration Announcement ·80
Optiscan Expands FDA Bid with New US Head and Neck Cancer StudyMedium
Optiscan launches U.S. head and neck cancer imaging study to support FDA submissions
1 Sept 2026 ·Clinical Study Initiation ·75
Optiscan Hits Halfway Point in Breast Cancer Imaging Study Ahead of FDA FilingsMedium
Optiscan reaches halfway recruitment milestone in breast cancer imaging study supporting FDA submissions
4 June 2026 ·Clinical Study Update ·75
Optiscan and Mayo Clinic Hit Two-Year Milestone in Robotic Surgery Imaging CollaborationMedium
Optiscan and Mayo Clinic mark two years of collaboration on robotic surgery imaging system
1 June 2026 ·Progress Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.